ZRC-3276 (nivolumab biosimilar) / Zydus Lifesci - LARVOL DELTA

Delhi HC Clears Zydus' Cancer Drug ZRC-3276 Despite BMS Patent Claim (Medical Dialogues) - "Zydus Lifesciences argued that although its product was a biosimilar of Nivolumab for regulatory purposes, it did not fall within the scope of the patent claims because it did not bind exclusively to PD-1 and showed statistically significant binding with other proteins belonging to the CD-28 family...The company argued that Bristol Myers Squibb had failed to map ZRC-3276 to the claims of Patent IN 340060, a requirement expressly mandated by Rule 3 (A)(ix) of the Delhi High Court Patent Suits Rules, 2022....With this ruling, the Delhi High Court has reaffirmed that patent enforcement must be grounded in strict claim analysis and balanced against public interest, especially where access to essential medicines and patient lives are at stake."

dMMR • Patent • Bladder Cancer • Classical Hodgkin Lymphoma • Colorectal Cancer • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Hepatocellular Cancer • Lung Non-Squamous Non-Small Cell Cancer • Malignant Pleural Mesothelioma • Melanoma • Microsatellite Instability • Non Small Cell Lung Cancer • Renal Cell Carcinoma • Urothelial Cancer